ThursdayOct 19, 2023 11:20 am

TinyGemsBreaks – GEMXX Corp. (GEMZ) Featured in Bell2Bell Podcast

GEMXX (OTC: GEMZ), a mine-to-market enterprise specializing in gold, gemstone and jewelry production, was featured in the latest episode of the Bell2Bell Podcast, a part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Richard Clowater, president of GEMXX, joined the program to share insight into the company, beginning the interview expounding on a recent news release detailing why management feels GEMXX is currently undervalued. “Since its inception, GEMXX has always looked for resource assets that are commercially viable. To date, we’ve acquired five properties, but only one of those properties has a partial assessment known…

Continue Reading

TuesdayOct 17, 2023 9:54 am

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) ‘Strikingly Different’ Road Tour Lands at Sonoma Motor Speedway

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is seeing a striking response to its Strikingly Different road tour, which is designed to offer potential customers and other interested individuals an opportunity to directly interact with its vehicles. The tour’s next stop is scheduled on Oct. 23–24, 2023, at the Sonoma Motor Speedway. Those registering to attend the event will be contacted to reserve specific time slots, which allows them toe test drive specific Mullen vehicles. Mullen FIVE/GT/GTRS reservation holders have priority for booking time slots. “Join us on an exhilarating journey across the United States as we bring…

Continue Reading

MondayOct 16, 2023 2:14 pm

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Reports on Status of Commercial Vehicle Production

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has released a commercial vehicle production update for its Class 3 EV cab chassis trucks and Class 1 EV cargo vans. According to the report, the company is on track to produce 150 Class 3 EV trucks through December 2023 and to begin production and delivery of its Class 1 EV cargo van in Q4 2023. Specifically, the report noted that the company’s Class 3 production plans for the remainder of 2023 include an estimated 150 vehicles to be produced and delivered to Randy Marion Automotive Group (“RMA”), noting that…

Continue Reading

MondayOct 16, 2023 12:36 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Innovative Glioblastoma Treatment ‘Could Offer Hope’

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is spotlighted in a recent article focused on glioblastoma, the most aggressive type of brain cancer. Noting that glioblastoma has an average survival of only 14 to 16 months after diagnosis, the article points out that currently, glioblastoma has no cure and, because it is a highly invasive tumor, complete surgical removal is difficult. “Even with aggressive treatment, the cancer tends to recur, leading to a grim prognosis,” the article states. “The high mortality rate of…

Continue Reading

MondayOct 16, 2023 11:33 am

TinyGemsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Adds Smallest Machine Yet to Crime-Fighting Portfolio

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, has announced that its crime-fighting tech portfolio is expanding with the addition of the K1 Hemisphere. According to the announcement, the K1 is the company’s smallest machine to date. The new ASR carries the slogan: Half a World of Information at Your Fingertips.  The announcement noted that the Hemisphere has undergone a rigorous product development cycle that included real-world testing by a client in Hawaii. After the evaluation period, Knightscope finalized production details and approved a full product release. According to the company, it…

Continue Reading

FridayOct 13, 2023 12:13 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Inks Global Collaboration, License Agreement with SulfoSyn

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has granted a new global, exclusive license to SulfoSyn Limited; the license is for the exclusive global use of all nonpharmaceutical applications of Lexaria’s proprietary DehydraTECH-sulforaphane, including the right to authorize sublicenses. According to the announcement, Lexaria has already received an up-front cash payment, and the agreement outlines minimumongoing payments, royalties and manufacturing revenues. Nonpharmaceutical uses could include supplements, additives, foods, dietary ingredients and more. In addition to the license agreement, the two companies have a broader agreement that, for at least the next two years, Lexaria will conduct certain…

Continue Reading

FridayOct 13, 2023 11:34 am

TinyGemsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Adds Two K5 ASR Contracts to Growing List of Clients

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, is continuing to add to its list of valued clients. The company has secured two more contracts for its K5 ASR, including a hotel in Athens, Georgia, and a Pre-K school in Vancouver, Washington. According to the announcement, the hospitality market is recognizing the many advantages that Knightscope ASRs offer. The company has a growing list of hotels, resorts and convention centers that are committed to guest safety and realize the key role that security robots can play in the mission. “Guest experience is a…

Continue Reading

ThursdayOct 12, 2023 1:30 pm

TinyGemsBreaks – Knightscope, Inc. (NASDAQ: KSCP) K5 ASRs and K1B Emergency Communications Systems Deployed for New and Existing Customers

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, announced two new sales for its K5 ASRs and an expansion sale from an existing user of its K1B line of emergency communication systems. The announcement reads, “Two Portland, Oregon, hotels each signed contracts for Knightscope ASRs to patrol their parking areas after the word-of-mouth-success of another Portland area hotel. Security in hospitality encompasses a hotel’s building and grounds as well as its guests, employees, visitors and day users. As recently outlined in Knightscope’s Blog, operators and administrators must follow an integrated approach…

Continue Reading

ThursdayOct 12, 2023 12:57 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Portfolio Expansion to 37 Granted Patents

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has been granted two new patents by the Canadian Intellectual Property Office (“CIPO”), increasing its portfolio to 37 granted patents. According to the update, Canadian Patent #2,984,917, “ Stable Ready-to-drink Beverage Compositions Comprising Lipophilic Active Agents, ” was granted on Sept. 26, 2023, and expires Dec. 1, 2036. The patent recognizes Lexaria’s innovations in delivering lipophilic (fat-based) active drugs and active molecules suspended in a water-based format. Lexaria’s DehydraTECH technology can be used in dry formats such as capsules and pills, as well as…

Continue Reading

WednesdayOct 11, 2023 1:34 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Rapid Pace of Enrollment in Potentially Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting enrollment of 229 participants in its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer; the company expects to ultimately enroll 243 in the study. Participants are being enrolled in 46 clinical trial sites across the United States, Italy, France, Spain and Switzerland. According to the announcement, CNS Pharmaceuticals is on track to achieve value-driving milestones before the end of the year, including…

Continue Reading

Contact us: (512) 354-7000